ClinicalTrials.gg
RecruitingNCT06155383Updated Dec 14, 2023

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

A Phase 2 interventional study of Capecitabine and oxaliplatin in Gastric Cancer and Gastroesophageal Junction Adenocarcinoma, sponsored by RemeGen Co., Ltd.. Recruiting at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-14.

Sponsored by RemeGen Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 100 studies testing capecitabine in Stomach Neoplasms — 9 open to participants now, 13 under way, 5 of them phase 3. Capecitabine · Stomach Neoplasms.

Planned enrollment
31st of 97
90 · median 50
Started
2023
with 1 other
Phase 2
58 of 100
4 open now
Primary completion
2025-01
later than 2 of 12 live
Registered
95th of 100
by date

Among the 100 studies testing capecitabine in Stomach Neoplasms, this one is the 31st largest by planned enrollment of the 97 interventional ones that give a count, is one of 2 that started in 2023, is one of 58 in phase 2, reaches primary completion later than 2 of the 12 other live ones, and was the 95th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

9 of the 100 studies testing capecitabine in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies testing capecitabine in Stomach Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of perioperative Disitamab Vedotin plus Toripalimab and XELOX versus Disitamab Vedotin plus Toripalimab versus XELOX in subjects with HER2-expressing resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.

Read the detailed description

This is an open-label, randomized, multicenter, open-label clinical trial designed to evaluate safety and efficacy of perioperative Disitamab Vedotin plus Toripalimab and XELOX versus Disitamab Vedotin plus Toripalimab versus XELOX in subjects with HER2-expressing (immunohistochemical 1+, 2+, 3+) resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.

03

Conditions studied

  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma

Browse trials for

Keywords

  • HER2-expressing
  • gastric cancer
  • gastroesophageal junction adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate and sign the form;
  2. Male or female, ≥18 years;
  3. Patients with gastric or gastroesophageal junction adenocarcinoma confirmed by histopathology;
  4. Clinical stage cT3-4aN+, no distant (M0);
  5. According to the baseline imaging and medical history data evaluated by the Investigators, radical surgery for gastric cancer and R0 resection is expected; Subjects had not previously received any antitumor therapy for gastric or gastroesophageal junction adenocarcinoma;
  6. - expression: IHC 1+, 2+, 3+;
  7. performance status score of 0 or 1;
  8. Cardiac function: ≥50%;
  9. The following criteria should be met within 7 days prior to study dosing (normal values are based on the clinical trial center):

    9.1Bone marrow function:

    1. (ANC) ≥1.5×109/L (no treatment with granulocyte colony-stimulating factor within 1 week prior to examination);
    2. ≥100×109/L (platelets should not be transfused within 1 week before the examination, and recombinant human thrombopoietin therapy should not be used within 2 weeks)
    3. ≥9g/dL (blood transfusion and erythropoietin treatment are not allowed within 2 weeks prior to the examination);

    9.2Liver function:

    1. Serum total ≤1.5 times the (ULN);
    2. alanine amino transferase () and aspartate amino transferase (AST) ≤2.5 × ULN;

    9.3 Kidney function:

    a.Blood creatinine ≤1.5×ULN or (CrCl) ≥50 mL/min according to Cockcroft-Gault formula method; Female: CrCl= (140-age) × weight (kg) × 0.85 72 × serum creatinine (mg/dL) Male: CrCl= (140-age) × weight (kg) × 1.00 72 × serum creatinine (mg/dL)

    9.4 Coagulation function:

    1. (PT) ≤1.5×ULN;
    2. thrombin time (TT) ≤ 1.5×ULN;
    3. activated partial thromboplastin time (APTT) ≤ 1.5×ULN.
  10. Female subjects should be surgically sterilized, , or agree to use at least one medically acceptable method of (e.g., intrauterine device, contraceptives, or condoms) for 7 days before the first dose and for 6 months after the end of the study treatment period, and not breastfeed. Blood pregnancy tests must be negative within 7 days prior to study enrollment. Male subjects should agree to use at least one medically approved contraceptive method (e.g., condoms, abstinence, etc.) for 7 days prior to initial dosing and up to 6 months after the end of the study treatment period;
  11. Able to understand trial requirements, willing and able to follow trial and follow-up procedures.

Exclusion criteria

Exclusion Criteria:

  1. Received any anti-tumor therapy for gastric or gastroesophageal junction adenocarcinoma before study dosing, including chemotherapy, radiotherapy, targeted therapy, immunotherapy and other anti-tumor drug therapy (including Chinese medicine treatment with anti-tumor ingredients specified in the instructions within 2 weeks before screening);
  2. The investigators considered perioperative period treatment of patients requiring radiotherapy for target lesions;
  3. Major surgery was performed within 4 weeks before the start of study dosing and did not fully recover;
  4. Patients with active gastrointestinal bleeding or high risk of bleeding within 2 weeks prior to screening;
  5. Gastrointestinal perforation/fistula 6 months before screening;
  6. Upper digestive tract obstruction that cannot guarantee drug absorption, functional abnormalities or malabsorption syndrome, which can affect the absorption of capecitabine ;
  7. Peripheral polyneuropathy ≥ NCI Ⅱ grade;
  8. Serum virology examination (based on the normal value of the research center):

    • Positive test with positive HBV DNA copy number;
    • Positive HCVAb test with positive PCR test.
    • Positive HIVAb test.
  9. Have received within 4 weeks prior to screening or plan to receive any vaccine during the study period (except for the novel coronavirus vaccine);
  10. Heart failure rated 3 or higher by the New York College of Cardiology ();
  11. Cardiac chest pain, defined as moderate pain that restricts daily activities, occurred within 28 days prior to screening. There were serious arteriovenous thrombosis events or cardiovascular and cerebrovascular accidents within six months before dosing, such as deep vein thrombosis (except asymptomatic and untreated intermuscular venous thrombosis), pulmonary embolism, cerebral infarction, cerebral hemorrhage, and myocardial infarction (except asymptomatic lacunar infarction that did not require clinical intervention);
  12. There is an active or advanced infection that requires systematic treatment (experimental medication may be initiated 2 weeks after the end of anti-infective therapy), such as active tuberculosis;
  13. There are systemic diseases that have not been stably controlled which are determined by investigators, including diabetes, hypertension, cirrhosis, etc.;
  14. A history of lung disease that requires treatment and has the potential to interfere with surgery, including but not limited to interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis, and acute lung disease;
  15. Active diseases requiring systemic therapy (such as the use of disease-modifying drugs, , or drugs) within 2 years prior to dose administration, and replacement therapies (e.g., thyroxine, insulin, or physiological replacement of glucocorticoids due to renal or pituitary deficiency) are allowed, and a history of autoimmune disease. Systemic use of steroids within 14 days prior to screening (dose > 10 mg/day prednisone or equivalent dose of other glucocorticoids) or other systemic immunosuppressive therapy;
  16. Other within 5 years prior to screening, other than those that have been cured after treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery);
  17. Previously received hematopoietic stem cell transplantation or solid organ transplantation;
  18. Allergies to any of the drugs in this study;
  19. Known deficiency of dipyrimidine dehydrogenase (DPD);
  20. Receiving immunotherapy (including but not limited to interleukin, interferon, thymus hormone) or other drugs within 28 days prior to screening;
  21. Pregnant or lactating women;
  22. Any other disease, metabolic disorder, or abnormal findings upon physical examination or laboratory examination that makes the subject unsuitable for receiving the investigational drug, affects the interpretation of study outcomes, or poses risks to patient safety, as determined by the investigator;
  23. Subject is assessed to be unable or unwilling to comply with the requirements of the protocol.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    XELOX (capecitabine + oxaliplatin)

    capecitabine with oxaliplatin arm

    Drug: Capecitabine · Drug: oxaliplatin

  • Experimental
    Disitamab Vedotin + Toripalimab

    Disitamab Vedotin with Toripalimab arm

    Drug: Disitamab Vedotin · Drug: Toripalimab

  • Experimental
    Disitamab Vedotin + Toripalimab + XELOX

    Disitamab Vedotin + Toripalimab + XELOX arm

    Drug: Capecitabine · Drug: oxaliplatin · Drug: Disitamab Vedotin · Drug: Toripalimab

Interventions

  • 1000 mg/m2, Bid orally, D1-14, every 3 weeks

  • 130 mg/m2, intravenous infusion, D1, every 3 weeks

  • 2.5 mg/kg, intravenous infusion, D1, every 2 weeks

    Also known as: RC48

  • 3.0 mg/kg, intravenous infusion, D1, every 2 weeks

    Also known as: JS001

06

What researchers measure

Primary outcomes

  1. Pathological complete response (pCR) rate

    Proportion of patients with pCR. pCR is defined as no invasive disease within an entirely submitted and evaluated gross lesion, and histologically negative nodes (ypT0N0)

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Objective remission rate (ORR)

    The objective response rate will be mainly analyzed by according to the RECIST 1.1 standard tumor evaluation by the investigator will be performed).

    Time frame: Up to approximately 2 years

  2. R0 resection rate

    Percentage of patients with complete resection of tumor tissue without tumor cell infiltration at surgical margins

    Time frame: Up to approximately 2 years

  3. Tumor regression grade (TRG) score

    to evaluate tumor regression grade (based on postoperative pathological reports);

    Time frame: Up to approximately 2 years

  4. Major pathological response (MPR)

    the proportion of patients with percentage of residual tumor cells in the tumor bed ≤10% after neoadjuvant therapy;

    Time frame: Up to approximately 2 years

  5. Event free survival (EFS)

    the time from randomization to the first occurrence of the following events: radiographic disease progression per RECIST 1.1,local or distant recurrence, and death due to any cause;

    Time frame: Up to approximately 2 years

  6. Overall survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 2 years

  7. Adverse events

    to evaluate safety including adverse event rate and adverse event grade

    Time frame: Time Frame: Up to approximately 2 years

07

Study locations

1 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Jan 2025, 14 months after the start.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's planned 14 months is below that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2023
First posted
Dec 4, 2023
StartActual
Nov 27, 2023
Primary completionEst.
Jan 31, 2025
CompletionEst.
Dec 31, 2027
Last update
Dec 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06155383
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Dec 4, 2023
Start date
Nov 27, 2023
Primary completion
Jan 31, 2025 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 14, 2023

Study contacts

Jianmin Fang, Ph.D
Contact
Jianminfang@hotmail.com
+8610-58075763
Jianmin Fang, Ph.D
study director · RemeGen Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Oxaliplatin · Disitamab vedotin · Toripalimab

Start the discussion